A methodology for examining the association between plasma volume and micronutrient biomarker mass and concentration in healthy eumenorrheic women

Sixtus Aguree1,2 and Alison D. Gernand2

1 Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, United States of America
2 Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, United States of America

ABSTRACT

Background. Accurate estimation and interpretation of nutritional biomarker concentrations are important in nutritional research, clinical care, and public health surveillance. Plasma volume (PV) may affect the interpretation of plasma biomarkers but is rarely measured. We aimed to examine the association between plasma volume (PV) and micronutrient biomarker concentrations and mass as part of pilot work to develop methods.

Methods. Nine healthy women with regular menstrual cycles provided fasting blood samples to measure micronutrient biomarkers. Indocyanine green was injected, and five timed blood draws were taken from 2 to 5 min to measure PV. Visits were scheduled around menstrual cycle day 2. Retinol, 25-hydroxyvitamin D, riboflavin, alpha-tocopherol, zinc, copper, magnesium, manganese, cobalt, iron, and ferritin concentrations were measured in serum. Total circulating micronutrient biomarker mass was calculated from PV and concentration.

Results. The mean PV was 2067 ± 470 mL. PV correlated positively with concentration of iron \( r = 0.87, P = 0.005 \); other correlations were weaker with \( p > 0.05 \). PV and total mass of retinol \( r = 0.90 \), 25(OH)D \( r = 0.75 \), zinc \( r = 0.88 \), copper \( r = 0.83 \), magnesium \( r = 0.93 \), manganese \( r = 0.72 \), and iron \( r = 0.92 \) were strongly correlated (all \( p < 0.05 \)). PV was positively correlated with circulating micronutrient mass for most biomarkers, implying that concentrations are maintained at different volumes of plasma. Larger studies are needed to further examine these relationships.

Conclusion. Though there appear to be some association between micronutrient biomarker mass and plasma volume, we are unable to draw a firm conclusion about any relationship from these results because of the small sample size. We consider these findings as a preliminary analysis to establish methods for future studies.
INTRODUCTION

Micronutrient status is commonly assessed by measuring circulating serum (or plasma) concentration of specific biomarkers related to the vitamin or mineral. Biomarker concentrations are used by health agencies and professional societies to set different cutoff values to define deficiency (Hess et al., 2007; IOM, 2001; WHO, 2004; WHO, 2009; WHO, 2011). Researchers and public officials use these cutoffs to examine the prevalence of nutritional deficiencies in a population and decide whether public health interventions are needed. For instance, serum zinc concentration is the standard biomarker for identifying zinc status in population studies, and values below 70 µg/dL are interpreted as deficient (Hess et al., 2007; IOM, 2001).

Physiologically, plasma volume (PV) could influence micronutrient biomarker concentrations because biomarkers are transported in plasma. For instance, during pregnancy, the rise in PV corresponds with a parallel increase in copper and a significant fall in zinc (Tuttle et al., 1985), folate (Hall, Pirani & Campbell, 1976), and hemoglobin (Gibson, 1973; Whittaker, Macphail & Lind, 1996) concentrations. It has also been reported that PV correlates with copper, ceruloplasmin, and zinc mass (Tuttle et al., 1985) during pregnancy. Studies assessing the relationship between micronutrient and plasma volume in non-pregnant women are scarce. Understanding how PV influences micronutrient biomarker concentrations in non-pregnant women will improve our understanding and interpretation of their nutrition status and will provide a strong basis for comparing changes occurring during pregnancy. As in pregnancy, PV (Bernstein, Ziegler & Badger, 2001; Cullinane et al., 1995) and micronutrient concentrations (Chandra, Gupta & Patel, 2017; Ha & Smith, 2003; Kim, Yetley & Calvo, 1993; Michos et al., 2010) may also vary across the menstrual cycle, which could affect how nutritional status is classified. Some studies have chosen to restrict all measurements to the early follicular phase for all study participants (Damron et al., 2004; Donckers et al., 2012; Krabbendam et al., 2009), which at least reduces the effect of menstrual cycle variation—which is estimated at 4–13% change in PV (Bernstein, Ziegler & Badger, 2001; Cullinane et al., 1995; Spaanderman et al., 2000).

Though research on PV has been encouraged, studies in both pregnant and non-pregnant women are scarce (Faupel-Badger et al., 2007; Schisterman, Mumford & Sjaarda, 2014), particularly so in non-pregnant women. This paper intended to measure PV and biomarkers in non-pregnant, healthy women of reproductive age under conditions where menstrual cycle variability in PV is limited by collecting data during a standard time during the menstrual cycle (i.e., the follicular phase). We hypothesized that PV would be associated with some but not all concentrations of nutritional biomarkers. This pilot study was conducted to generate preliminary data on the association between PV and micronutrient biomarkers in non-pregnant, healthy women of reproductive age to set the stage for a larger study across the menstrual cycle.
MATERIALS & METHODS

Subjects
Nine healthy women with a regular menstrual cycle participated in this pilot study. Inclusion criteria for the study were as follows: (1) age 18–35 y, (2) regular menstrual cycle (26–35 days), (3) general good health (does not have a known, ongoing health condition/medical issue that requires regular monitoring by a doctor) (4) BMI from 18.5 to 29.9 kg/m², (5) nonsmoking, 76) non-pregnant, and (7) if ever pregnant, last pregnancy ended >12 months before enrollment. Exclusion criteria for the study were as follows: (1) known allergy to shellfish or iodine, (2) blood pressure on the day of measurements was low or high (SBP <90 or >140 mmHg and/or DBP <60 or >90 mmHg), (3) current hypertension or previous hypertensive disorder in pregnancy (gestational hypertension or preeclampsia), (4) taking regular physician-prescribed medication(s) for a health condition, (5) trying to conceive, (6) using hormonal birth control (within the past three months), or (7) currently breastfeeding.

Ethics approval and consent to participate
The protocol was approved by The Office for Research Protections (ORP) at the Pennsylvania State University (STUDY00004051) and conducted in line with the Declaration of Helsinki. All participants provided written informed consent before enrolling in the study.

Study design
Participants responded to the study advertisements seeking healthy female volunteers in the State College, Pennsylvania area. The participants were pre-screened via telephone. Those eligible were scheduled to visit the Clinical Research Center (CRC), a service unit in The Pennsylvania State University’s Clinical and Translational Science Institute, University Park, PA, where the study was conducted. Participants came to the CRC in the morning after a 12-hour overnight fast. Study visits were scheduled to occur at menstrual cycle day 2 (the second day from the start of menstrual blood flow as reported by the participant) to 5 to remove the effect of menstrual cycle phase variability, if any, on micronutrient concentrations and PV. One participant was measured on cycle day 9 because that was the only day that she was available. Participants completed a brief questionnaire that included socio-demographics, health history, and pregnancy history, and a trained study staff measured their weight, height, and percent body fat (assessed using bioelectric impedance analyzer) using a standard protocol. They also provided a urine sample for a pregnancy test. Participants then rested in a supine position on a bed in preparation for an intravenous (IV) catheter insertion and blood collection.

Blood collection and PV determination
After 15 min of rest, an IV was inserted in the left or right antecubital vein. We collected participants’ blood into three different tubes; 6 mL EDTA-free evacuated trace element free tubes and 6 mL and 2 mL EDTA-containing evacuated trace element free tubes for serum, plasma, and whole blood, respectively. Detailed methods of our PV protocol based
on the indicator-dilution principle are published elsewhere (Aguree & Gernand, 2019). In brief, a bolus dose of indocyanine green (ICG, IC-GREEN, AKORN Inc, Lake Forest, IL, USA) (0.25 mg/kg body weight) was injected into the IV and flushed with saline solution. From 2 to 5 min after injection, blood samples were collected at intervals of ~45 s into a 3 mL EDTA tube (5 tubes total). Plasma was obtained from the 6 mL (pre-injection) and 3 mL (post-injection) EDTA tubes and used to determine PV within 2 h of blood collection.

**Measurement of micronutrient biomarkers**

Whole blood was run for a complete blood count using the Beckman Coulter Ac-T Diff 2 hematology analyzer (Beckman Coulter Inc, Brea, CA, USA) with 3-level quality-control materials (Beckman Coulter, Inc. Brea, CA) within one hour of blood collection. Serum zinc and copper concentrations were measured using flame atomic absorption spectroscopy on an AAnalyst 400 Spectrometer (PerkinElmer, Inc., Waltham, MA, USA). Serum retinol concentration was measured using ultra performance liquid chromatography (ACQUITY UPLC System, Waters Corporation, Milford, MA, USA). We used quality control samples from the National Institute of Standards and Technology (NIST) reference materials (SRM® 1950, Gaithersburg, Maryland, USA) for the analysis of serum retinol, zinc, and copper.

The concentrations of serum magnesium, manganese, cobalt, and iron were analyzed using inductively coupled plasma mass spectrometry (ICP-MS) with collision cell technology (CCT), using a Thermo Fisher Scientific X Series 2 (Thermo Fisher Scientific, Lanham, MD, USA) with an ASX 250 autosampler, in the Laboratory for Isotopes and Metals in the Environment (LIME) at The Pennsylvania State University. The method was adapted from previous studies (Bumoko et al., 2015; Cao et al., 2019; Muñiz et al., 2001). In brief, serum samples were diluted 25-fold with 0.1 N HNO₃ (trace metal grade, Fisher Scientific) in 15 mL trace mineral-free centrifuge tubes and stored for 24 h before analysis. Control samples (seronorm L-2; Seronorm™ Trace Elements Serum; SERO AS, Billingstad, Norway) were treated, prepared, and analyzed by the same method as the participant samples.

Serum ferritin and soluble serum transferrin receptor (sTfR) were measured using enzyme-linked immunosorbent assay (ELISA) methods (Ramco Laboratories, Inc., Strafford, Texas, USA). We used commercial ELISA kits to measure serum AGP (Kent Laboratories Inc., Bellingham, Washington) and CRP (Kent Laboratories Inc., Bellingham, Washington, USA). A DEQAS (the Vitamin D External Quality Assessment Scheme) certified laboratory—the Analytical Facility for Bioactive Molecules Laboratory at The Hospital for Sick Children in Toronto, Canada—measured serum concentration 25-hydroxyvitamin D, 3-epi-25(OH)D₃, α-tocopherol, and riboflavin assays for the current study.

The following cutoffs were used: marginal vitamin A deficiency, serum retinol <0.70 µmol/L (Pee & Dary, 2002); vitamin D deficiency, 25-hydroxyvitamin D <30 nmol/L (IOM, 2011); inadequate vitamin E, α-tocopherol <12 µmol/L (IOM, 2000); zinc deficiency, serum zinc concentration <70 µg/dL (Hess et al., 2007; IOM, 2001); copper deficiency, serum copper <10.0 µmol/L (IOM, 2001); and iron-deficiency, serum ferritin
concentration <15 µg/L (WHO, 2011); We defined signs of inflammation as CRP >5.0 mg/L or AGP >1.0 mg/L (WHO/CDC, 2007), and sTfR >8.3 mg/L (Grant et al., 2012). Body iron was estimated using the Cook’s equation (Cook, Flowers & Skikne, 2003).

**Statistical analysis**

Arithmetic means and standard deviations (mean ± SD), median (IQR), geometric means (95% CIs), and range (minimum, maximum) were reported for biomarker concentrations and mass (see Fig. S1. Q-Q plots and kernel density plots for biomarker concentrations and mass). Because serum ferritin, zinc, and retinol are known to be influenced by inflammation (Stephensen & Gildengorin, 2000; Thurnham, 2014; Thurnham et al., 2010), measured values were corrected for inflammation (CRP and AGP values) using external correction factors (Fiorentino et al., 2018; Thurnham et al., 2003). The total circulating mass for each biomarker was estimated as the product of the PV and biomarker concentration:

\[
\text{Biomarker mass} = \text{PV} \times \text{biomarker concentration}
\]

A Spearman correlation coefficient was computed to assess the relationship between PV and each of the micronutrient biomarkers (concentration and mass). Data were analyzed using Stata version 14 (Stata-Corp., College Station, Texas, USA), and statistical significance (a 2-sided test) was determined based on a nominal level of alpha equal to 0.05.

**RESULTS**

The mean age (years), BMI, percent body fat (%), and PV were 25.0 ± 4.5 years, 23.5 ± 2.9 kg/m² (two women had BMI of 26.1, and 29.6, the rest were between 20.3 to 24.2 kg/m²), 28.6 ± 5.0%, and 2067 ± 470 mL, respectively. Eight women self-identified as white and one as African-American. All women were nulliparous except one. Two women were classified as overweight; the other seven were normal weight. The concentrations of the biomarkers were within normal ranges (Table 1). CRP was undetectable for all subjects; two participants had elevated AGP concentrations. Summary statistics of parameters from complete blood cell counts were within normal ranges and are reported in Table S1.

Three women had zinc deficiency, and an equal number were anemic. Only one woman had vitamin D insufficiency, but none were deficient. None of the participants were deficient in iron (by ferritin), vitamin E, vitamin A or copper. The geometric mean of body iron was 3.50 mg/kg (95% CI [1.35–9.08]); one person was iron deficient using body iron (<0 mg/kg).

Overall, the relationships between PV and biomarker mass were stronger than the relationships between PV and biomarker concentrations (Table 2). Correlations between PV and micronutrient biomarker concentrations ranged in absolute value from 0.03 to 0.87, with five negative associations. Only serum iron concentration was statistically significantly correlated with PV. The correlations between biomarker mass and PV ranged from 0.35 to 0.93; all correlations were positive, and nine were statistically significant (retinol, 25(OH)D, α-tocopherol, zinc, copper, magnesium, manganese, iron, and hemoglobin mass).
Table 1  Micronutrient biomarker concentrations and mass in reproductive-age women (n = 9).a

| Biomarker                  | Mean ± SD | Median (IQR) | GM (95% CI)b | Range c |
|----------------------------|-----------|--------------|--------------|---------|
| **Concentration of biomarkers** |           |              |              |         |
| Retinol, µg/dL             | 38.4 ± 6.9 | 36.7 (33.0, 42.2) | 37.9 [33.1, 43.3] | 29.3–52.8 |
| 25(OH)D₃, nmol/L          | 75.7 ± 28.1 | 79.4 (52.7, 100.1) | 70.2 [50.2, 98.3] | 29.0–112.6 |
| 3-epi-25(OH)D₃, nmol/L    | 3.3 ± 2.5  | 2.5 (1.9, 4.1)  | 2.8 [1.7, 4.4]  | 1.2–9.5  |
| Riboflavin, nmol/L        | 19.1 ± 7.6 | 18.0 (13.8, 22.3) | 18.1 [13.8, 23.6] | 11.3–36.4 |
| α-tocopherol, µmol/L      | 21.7 ± 6.0 | 20.2 (16.1, 27.5) | 21.0 [17.1, 25.8] | 15.3–31.7 |
| Zinc, µg/dL               | 77.1 ± 12.5 | 83.0 (64.0, 89.0) | 76.2 [66.9, 86.8] | 59.0–89.5 |
| Copper, µg/dL             | 106.6 ± 15.2 | 102.2 (95.7, 120.5) | 105.7 [95.1, 117.5] | 88.4–132.2 |
| Magnesium, mg/L           | 26.6 ± 2.4  | 27.5 (24.4, 28.5) | 26.5 [24.7, 28.5] | 22.6–29.9 |
| Manganese, ng/mL          | 2.6 ± 0.4   | 2.5 (2.5, 2.8)  | 2.6 [2.4, 2.9]  | 2.3–3.5  |
| Cobalt, ng/mL             | 1.2 ± 0.4   | 1.1 (0.8, 1.5)  | 1.1 [0.9, 1.4]  | 0.8–1.8  |
| Iron, µg/dL               | 123.4 ± 39.2 | 120.5 (92.4, 148.2) | 118.2 [93.1, 150.1] | 76.3–202.4 |
| Ferritin, ng/mL           | 25.9 ± 16.4 | 20.9 (9.7, 40.5)  | 21.1 [12.2, 36.4] | 7.9–52.0  |
| sTfRd mg/L                | 5.2 ± 3.6   | 3.9 (3.3, 5.0)  | 4.5 [3.0, 6.8]  | 3.0–14.0  |
| Hemoglobind g/dL          | 12.3 ± 0.7  | 12.1 (11.8, 12.8) | 12.2 [11.7, 12.8] | 11.3–13.4 |
| Hematocritd, %            | 37.1 ± 2.3  | 37.6 (34.6, 38.7) | 37.0 [35.2, 39.0] | 34.4–40.5 |
| **Circulating mass of biomarkers** |           |              |              |         |
| Retinol, µg               | 800.6 ± 287.2 | 661.6 (636.3, 951.2) | 764.5 [604.1, 967.3] | 550.8–1468.0 |
| 25(OH)D₃, µg              | 64.2 ± 29.8  | 59.0 (40.9, 94.2)  | 56.8 [36.8, 87.8]  | 17.4–106.0 |
| 3-epi-25(OH)D₃, µg        | 2.8 ± 2.0    | 2.3 (1.4, 3.3)   | 2.2 [1.3, 3.8]   | 0.7–7.6   |
| Riboflavin, µg            | 14.5 ± 6.0   | 11.8 (10.6, 17.7) | 13.6 [10.4, 17.8] | 10.1–27.2 |
| α-tocopherol, mg          | 18.6 ± 3.5   | 19.4 (15.7, 21.1) | 18.3 [15.8, 21.2] | 13.3–24.2 |
| Zinc, mg                  | 1.6 ± 0.5    | 1.8 (1.1, 2.0)   | 1.5 [1.2, 2.0]   | 0.9–2.5   |
| Copper, mg                | 2.2 ± 0.6    | 2.1 (1.7, 2.5)   | 2.1 [1.7, 2.6]   | 1.5–3.5   |
| Magnesium, mg             | 55.5 ± 15.6  | 55.2 (40.8, 68.8) | 53.6 [43.0, 66.8] | 36.1–79.7 |
| Manganese, µg             | 5.4 ± 1.2    | 5.5 (4.4, 6.3)   | 5.3 [4.5, 6.3]   | 3.8–7.2   |
| Cobalt, µg                | 2.4 ± 0.9    | 2.6 (1.4, 3.0)   | 2.3 [1.6, 3.1]   | 1.2–4.0   |
| Iron, mg                  | 2.7 ± 1.4    | 2.4 (1.4, 3.8)   | 2.4 [1.6, 3.6]   | 1.2–5.4   |
| Ferritin, µg              | 55.7 ± 39.5  | 45.2 (19.2, 88.2) | 42.6 [22.7, 79.8] | 12.7–124.8 |
| sTfRd mg                  | 10.2 ± 7.2   | 7.6 (5.8, 11.5)  | 8.8 [5.6, 13.9]  | 4.8–27.1  |
| Hemoglobind g             | 365.2 ± 91.2 | 346.0 (297.1, 404.2) | 356.6 [294.8, 431.2] | 279.9–558.8 |

**Notes.**
- IQR, Interquartile range (lower quartiles, upper quartiles); GM, geometric mean; 25(OH)D₃, 25-hydroxyvitamin D₃; 3-epi-25(OH)D₃, 3-epi-25-hydroxyvitamin D₃; sTfR, serum soluble transferrin receptor; Biomarker mass, PV*BioMarker concentration.
- aAll biomarkers were measured in serum, except for hemoglobin which was obtained from whole blood.
- bValues are geometric mean (lower 95% CI of geometric mean, upper 95% CI of geometric mean).
- cRange (minimum value, maximum value).
- dData available for eight subjects.
- eMass estimated as BV*hemoglobin concentration (where BV, blood volume; PV, plasma volume; hct, hematocrit (%)).

**DISCUSSION**

The purpose of this study was to examine the relationship between PV and micronutrient biomarker concentrations to provide a direction for future large studies. Overall, PV showed a strong positive correlation with the circulating mass of the micronutrients under consideration. But the micronutrient concentrations were not associated with PV.
### Table 2  Spearman’s correlation coefficients of PV with concentration and mass of micronutrient biomarkers in reproductive-age women (n = 9).\(^a\)

| Biomarker            | Concentration (r) | Circulating mass (r) |
|----------------------|-------------------|----------------------|
| **Concentration of biomarkers** |                   |                      |
| Retinol, \(\mu\)g/dL | 0.03              |                      |
| 25(OH)D3, nmol/L     | 0.33              |                      |
| 3-epi-25(OH)D3, nmol/L | 0.28             |                      |
| Riboflavin, nmol/L   | -0.40             |                      |
| \(\alpha\)-tocopherol, \(\mu\)mol/ L | -0.53          |                      |
| Zinc, \(\mu\)g/dL    | 0.59              |                      |
| Copper, \(\mu\)g/dL  | 0.03              |                      |
| Magnesium, mg/L      | 0.43              |                      |
| Manganese/mL         | -0.08             |                      |
| Cobalt, ng/mL        | 0.26              |                      |
| Iron, \(\mu\)g/dL    | 0.87              |                      |
| Ferritin, ng/mL      | 0.25              |                      |
| \(sTfR\)\(^b\), mg/L | 0.26             |                      |
| Hemoglobin\(^b\), g/dL | -0.11           |                      |
| Hematocrit\(^b\), %  | -0.04             |                      |
| **Circulating mass of biomarkers** |                   |                      |
| Retinol, \(\mu\)g    | 0.90              |                      |
| 25(OH)D3, \(\mu\)g    | 0.75              |                      |
| 3-epi-25(OH)D3, \(\mu\)g | 0.53          |                      |
| Riboflavin, \(\mu\)g  | 0.62              |                      |
| \(\alpha\)-tocopherol, mg | 0.35           |                      |
| Zinc, mg             | 0.88              |                      |
| Copper, mg           | 0.83              |                      |
| Magnesium, mg        | 0.93              |                      |
| Manganese, \(\mu\)g  | 0.72              |                      |
| Cobalt, \(\mu\)g     | 0.53              |                      |
| Iron, mg             | 0.92              |                      |
| Ferritin, \(\mu\)g   | 0.57              |                      |
| \(sTfR\)\(^b\), mg   | 0.62              |                      |
| Hemoglobin\(^b\), g\(^d\) | 0.90          |                      |

**Notes.**

25(OH)D3, 25-hydroxyvitamin D3; 3-epi-25(OH)D3, 3-epi-25-hydroxyvitamin D3; \(sTfR\), serum soluble transferrin receptor.

\(^a\) Biomarker mass=PV* Biomarker concentration.

\(^b\) All biomarkers were measured in serum, except for hemoglobin which was obtained from whole blood.

\(^c\) Data available for eight subjects.

\(^d\) Statistical significance (a 2-sided test) was determined based on a nominal level of alpha equal to 0.05.

\(^e\) Mass estimated as BV*hemoglobin concentration (where BV, blood volume; PV, plasma volume; hct, hematocrit (%)).
mean values from the present study are consistent with previously reported values for manganese (Romero et al., 2001; Wang, Du & Zheng, 2008), iron (Næss-Andresen et al., 2019), magnesium (Lowenstein & Stanton, 1986), zinc (Hennigar et al., 2018; Rükgauer, Klein & Kruse-Jarres, 1997), copper (Rükgauer, Klein & Kruse-Jarres, 1997), iron (Dale, Burritt & Zinsmeister, 2002), ferritin (Belza et al., 2005; Milman et al., 2017; Næss-Andresen et al., 2019), retinol (Browne et al., 2008; Gillespie et al., 2004; Stephensen & Gildengorin, 2000; Talwar et al., 2005), and alpha-tocopherol (Ford et al., 2006). Data on circulating plasma mass is limited, and therefore, it is difficult to make comparisons with our study. The mean circulating zinc mass estimated for this study is similar to those reported in the literature (1.5 to 2.5 g) (Brown et al., 2004; Jackson, 1989; Linder, 1991). The mean value of circulating iron mass, 2.7 mg, is consistent with the commonly quoted value of 2–4 mg (Ganz, 2013). These findings show that PV may be associated with the circulating mass of many micronutrient biomarkers but not their concentrations. Specifically, high PV was associated with elevated circulating masses of retinol, 25(OH)D, zinc, copper, magnesium, manganese, iron, and hemoglobin mass.

Physiologically, these findings suggest that the body can adjust to different PV levels, thereby maintaining the micronutrient concentration. At the same time, the amount of circulating mass contracts or expands to help support its function. High PV was associated with a low concentration of some biomarkers (α-tocopherol) while showing a positive association with the biomarker mass. This inverse association suggests a possible dilution effect of PV on the biomarker concentration such that a woman may have normal circulating mass of the biomarker but lower concentration. For biomarkers such as riboflavin and sTfR, the lack of association between biomarker mass and PV could be due to the small sample size, that could be clarified in larger studies.

Given the small sample size, it is unclear if the relationship between PV and biomarkers concentrations (or mass) were distorted by some other factors such as high BMI (overweight) and inflammation. We report statistical testing and $p$ values to aid in future work, however we recognize that corrections for multiple testing should be applied if this were not a pilot study.

Though our previous study reported a small non-significant decrease in plasma volume across the menstrual cycle, it is unknown how that may influence micronutrient biomarker concentrations and circulating mass (Aguree et al., 2020). Future studies should be designed (with appropriate statistical power) to clarify whether PV influences micronutrient concentrations and how BMI and inflammation affect these relationships. Despite the challenges with verifying menstrual cycle phases and the variations that may occur in PV throughout the menstrual cycle, this type of work is needed. Future studies should examine factors (e.g., sex hormones concentrations) that contribute to alterations in micronutrient concentration with plasma volume at different time points across the menstrual cycle, and how they are related.

**Limitations**

Though carefully designed, the sample size was small; therefore, more extensive studies should explore these relationships across the menstrual cycle.
CONCLUSIONS

This pilot study was designed to develop a method for examining the association between PV and nutritional biomarkers during the early follicular phase of the menstrual cycle. We found that PV was positively correlated with the circulating mass of micronutrient biomarkers in healthy women. PV was not associated with micronutrient concentrations except serum iron. Given the small sample size of the study, we are unable to draw a firm conclusion about any relationship from these results, instead we consider this as a preliminary analysis to establish methods for future studies.

ACKNOWLEDGEMENTS

We thank the medical staff, especially Cyndi Flanagan, at the Clinical Research Center of the Pennsylvania State University’s Clinical and Translational Science Institute. We also extend our gratitude to Dr. James A. Pawelczyk, Associate Professor of Physiology and Kinesiology at The Pennsylvania State University, for his support in the study design, particularly on the use of indocyanine green. Our gratitude goes to Dr. A. Catharine Ross, whose laboratory measured retinol, and to Dr. Laura E. Murray-Kolb, whose laboratory measured the iron biomarkers for this work. We wish to thank Hayley Craig-Barnes of the Analytical Facility for Bioactive Molecules of The Centre for the Study of Complex Childhood Diseases, The Hospital for Sick Children, Toronto, Canada, for measurements of 25(OH)D, riboflavin, and alpha-tocopherol concentrations. The authors sincerely acknowledge the research support provided by several research assistants, particularly Leigh A. Taylor. We also thank the volunteers for their participation in the study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by the College of Health and Human Development, The Pennsylvania State University. Additionally, the project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
College of Health and Human Development, The Pennsylvania State University.
National Center for Advancing Translational Sciences.
National Institutes of Health, through Grant: UL1 TR002014.

Competing Interests

The authors declare there are no competing interests.
Author Contributions

- Sixtus Aguree conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Alison D. Gernand conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The protocol was approved by The Office for Research Protections (ORP) at the Pennsylvania State University (STUDY00004051).

Data Availability

The following information was supplied regarding data availability:

Data are available in the Supplemental Files and Figshare:
Aguree, Sixtus (2020): Plasma volume and micronutrient biomarker data. Figshare. Dataset. https://doi.org/10.6084/m9.figshare.13249574.v1.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10535#supplemental-information.

REFERENCES

Aguree S, Bethancourt HJ, Taylor LA, Rosinger AY, Gernand AD. 2020. Plasma volume variation across the menstrual cycle among healthy women of reproductive age: a prospective cohort study. Physiological Reports 8:e14418 DOI 10.14814/phy2.14418.

Aguree S, Gernand AD. 2019. An efficient method for measuring plasma volume using indocyanine green dye. Methods 6:1072–1083 DOI 10.1016/j.mex.2019.05.003.

Belza A, Henriksen M, Ersbøll AK, Thilsted SH, Tetens I. 2005. Day-to-day variation in iron-status measures in young iron-deplete women. British Journal of Nutrition 94:551–556 DOI 10.1079/BJN20051461.

Bernstein IM, Ziegler W, Badger GJ. 2001. Plasma volume expansion in early pregnancy. Obstetrics and Gynecology 97:669–672 DOI 10.1016/s0029-7844(00)01222-9.

Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lönnerdal B, Ruel MT, Sandström B, Wasantwisut E, Hotz C, (IZiNCG) IZNCG. 2004. Overview of zinc nutrition. Food and Nutrition Bulletin 25:599–S129 DOI 10.1177/15648265040251S204.

Browne RW, Bloom MS, Schisterman EF, Hovey K, Trevisan M, Wu C, Liu A, Wactawski-Wende J. 2008. Analytical and biological variation of biomarkers of oxidative stress during the menstrual cycle. Biomarkers 13(2):160–183 DOI 10.1080/13547500701775563.

Bumoko GM, Sadiki NH, Rwatambuga A, Kayembe KP, Okitundu DL, MumbaNgoyi D, Muyembe JJ, Banea JP, Boivin MJ, Tshala-Katumbay D. 2015. Lower
serum levels of selenium, copper, and zinc are related to neuromotor impairments in children with konzo. *Journal of the Neurological Sciences* **349**:149–153 DOI 10.1016/j.jns.2015.01.007.

Cao B, Yan L, Ma J, Jin M, Park C, Nozari Y, Kazmierczak OP, Zuckerman H, Lee Y, Pan Z, Brietzke E, McIntyre RS, Lui LMW, Li N, Wang J. 2019. Comparison of serum essential trace metals between patients with schizophrenia and healthy controls. *Journal of Trace Elements in Medicine and Biology* **51**:79–85 DOI 10.1016/j.jtemb.2018.10.009.

Chandra S, Gupta N, Patel S. 2017. Study of iron status indicators in different phases of menstrual cycle in first year medical college females. *International Journal of Research in Medical Sciences* **5**(1):46–49 DOI 10.18203/2320-6012.ijrms20164520.

Cook JD, Flowers CH, Skikne BS. 2003. The quantitative assessment of body iron. *Blood* **101**:3359–3364 DOI 10.1182/blood-2002-10-3071.

Cullinane EM, Yurgalevitch SM, Saritelli AL, Herbert PN, Thompson PD. 1995. Variations in plasma volume affect total and low-density lipoprotein cholesterol concentrations during the menstrual cycle. *Metabolism* **44**:965–971 DOI 10.1016/0026-0495(95)90090-x.

Dale JC, Burritt MF, Zinsmeister AR. 2002. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. *American Journal of Clinical Pathology* **117**:802–808 DOI 10.1309/2YT4-CMP3-KYW7-9RK1.

Damron DP, Bernstein IM, Shapiro RE, Schonberg A. 2004. Uterine blood flow response to alpha-adrenergic blockade in nulligravid women of reproductive age. *Journal of the Society for Gynecologic Investigation* **11**:388–392 DOI 10.1016/j.jsgi.2004.02.009.

Donckers J, Scholten RR, Oyen WJ, Hopman MT, Lotgering FK, Spaanderman ME. 2012. Unexplained first trimester recurrent pregnancy loss and low venous reserves. *Human Reproduction* **27**:2613–2618 DOI 10.1093/humrep/des245.

Faupel-Badger JM, Hsieh CC, Troisi R, Lagiou P, Potischman N. 2007. Plasma volume expansion in pregnancy: implications for biomarkers in population studies. *Cancer Epidemiology Biomarkers and Prevention* **16**:1720–1723 DOI 10.1158/1055-9965.EPI-07-0311.

Fiorentino M, Perignon M, Kuong K, Chamnan C, Berger J, Wieringa FT. 2018. Subclinical inflammation affects iron and vitamin A but not zinc status assessment in Senegalese children and Cambodian children and women. *Public Health Nutrition* **21**:1266–1277 DOI 10.1017/S1368980017003809.

Ford ES, Schleicher RL, Mokdad AH, Ajani UA, Liu S. 2006. Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. *American Journal of Clinical Nutrition* **84**:375–383 DOI 10.1093/ajcn/84.1.375.

Ganz T. 2013. Systemic iron homeostasis. *Physiological Reviews* **93**:1721–1741 DOI 10.1152/physrev.00008.2013.

Gibson HM. 1973. Plasma-Volume and Glomerular-Filtration Rate in Pregnancy and Their Relation to Differences in Fetal Growth. *Journal of Obstetrics & Gynaecology of the British Commonwealth* **80**:1067–1074 DOI 10.1111/j.1471-0528.1973.tb02981.x.
Gillespie C, Ballew C, Bowman BA, Donehoo R, Serdula MK. 2004. Intraindividual variation in serum retinol concentrations among participants in the third National Health and Nutrition Examination Survey, 1988–1994. *American Journal of Clinical Nutrition* 79:625–632 DOI 10.1093/ajcn/79.4.625.

Grant FK, Martorell R, Flores-Ayala R, Cole CR, Ruth LJ, Ramakrishnan U, Suchdev PS. 2012. Comparison of indicators of iron deficiency in Kenyan children. *American Journal of Clinical Nutrition* 95:1231–1237 DOI 10.3945/ajcn.111.029900.

Ha EJ, Smith AM. 2003. Plasma selenium and plasma and erythrocyte glutathione peroxidase activity increase with estrogen during the menstrual cycle. *Journal of the American Journal of Clinical Nutrition* 22:43–51 DOI 10.1080/07315724.2003.10719274.

Hall MH, Pirani BBK, Campbell D. 1976. The Cause of the fall in serum folate in normal pregnancy. *British Journal of Obstetrics and Gynaecology* 83:132–136 DOI 10.1111/j.1471-0528.1976.tb00794.x.

Hennigar SR, Lieberman HR, Fulgoni3rd VL, McClung JP. 2018. Serum zinc concentrations in the US population are related to sex, age, and time of blood draw but not dietary or supplemental zinc. *Journal of Nutrition* 148:1341–1351 DOI 10.1093/jn/nxy105.

Hess SY, Peerson JM, King JC, Brown KH. 2007. Use of serum zinc concentration as an indicator of population zinc status. *Food and Nutrition Bulletin* 28:S403–S429 DOI 10.1177/15648265070283S303.

IOM. 2000. *Food and nutrition board. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids*. Washington, D.C.: National Academies Press.

IOM. 2001. *Institute of medicine, food and nutrition board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicone, vanadium, and zinc*. Washington, D.C.: National Academies Press.

IOM. 2011. *Institute of medicine, food and nutrition board. dietary reference intakes for calcium and vitamin D*. Washington, D.C.: National Academies Press.

Jackson MJ. 1989. Physiology of zinc: general aspects. In: Mills CF, ed. *Zinc in Human Biology*. London: Springer-Verlag, 1–14.

Kim I, Yetley EA, Calvo MS. 1993. Variations in iron-status measures during the menstrual cycle. *American Journal of Clinical Nutrition* 58:705–709 DOI 10.1093/ajcn/58.5.705.

Krabbendam I, Courtar DA, Janssen BJA, Aardenburg R, Peeters LLH, Spaanderman MEA. 2009. Blunted autonomic response to volume expansion in formerly preeclamptic women with low plasma volume. *Reproductive Sciences* 16:105–112 DOI 10.1177/1933719108324136.

Linder MC. 1991. Nutrition and metabolism of the trace elements. In: Linder MC, ed. *Nutritional biochemistry and metabolism: with clinical applications*. New York: Elsevier, 215–276.

Lowenstein FW, Stanton MF. 1986. Serum magnesium levels in the United States, 1971–1974. *Journal of the American College of Nutrition* 5:399–414 DOI 10.1080/07315724.1986.10720143.
Michos C, Kalfakakou V, Karkabounas S, Kiortsis D, Evangelou A. 2010. Changes in copper and zinc plasma concentrations during the normal menstrual cycle in women. *Gynecological Endocrinology* 26:250–255 DOI 10.3109/09513590903247857.

Milman N, Taylor CL, Merkel J, Brannon PM. 2017. Iron status in pregnant women and women of reproductive age in Europe. *American Journal of Clinical Nutrition* 106:165S–166S DOI 10.3945/ajcn.117.156000.

Muñiz CSF-MJ, Marchante-Gayón JM, García Alonso JI, Cannata-Andia JB, Sanz-Medel A. 2001. Reference values for trace and ultratrace elements in human serum determined by double-focusing ICP-MS. *Biological Trace Element Research* 82:259–272 DOI 10.1385/BTER:82:1-3:259.

Næss-Andresen M-L, Eggemoen AR, Berg JP, Falk RS, Jenum AK. 2019. Serum ferritin, soluble transferrin receptor, and total body iron for the detection of iron deficiency in early pregnancy: a multiethnic population-based study with low use of iron supplements. *The American Journal of Clinical Nutrition* 109:566–575 DOI 10.1093/ajcn/nqy366.

Ness-Andresen M-L, Eggemoen AR, Berg JP, Falk RS, Jenum AK. 2019. Serum ferritin, soluble transferrin receptor, and total body iron for the detection of iron deficiency in early pregnancy: a multiethnic population-based study with low use of iron supplements. *The American Journal of Clinical Nutrition* 109:566–575 DOI 10.1093/ajcn/nqy366.

Pee SD, Dary O. 2002. Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. *Journal of Nutrition* 132:2895S–2901S DOI 10.1093/jn/132.9.2895S.

Romero CD, Sanchez PH, Blanco FL, Rodriguez ER, Majem LS. 2001. Serum manganese concentrations in a representative sample of the Canarian population. *Biological Trace Element Research* 80:43–51 DOI 10.1385/BTER:80:1:43.

Rükgauer M, Klein J, Kruse-Jarres JD. 1997. Reference values for the trace elements copper, manganese, selenium, and zinc in the serum / plasma of children, adolescents, and adults. *Journal of Trace Elements in Medicine and Biology* 11:92–98 DOI 10.1016/s0946-672x(97)80032-6.

Schisterman EF, Mumford SL, Sjaarda LA. 2014. Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women. *Epidemiologic Reviews* 36:71–82 DOI 10.1093/epirev/mxt007.

Spaanderman ME, Van Beek E, Ekhart TH, Van Eyck J, Cherix EC, De Leeuw PW, Peeters LL. 2000. Changes in hemodynamic parameters and volume homeostasis with the menstrual cycle among women with a history of preeclampsia. *American Journal of Obstetrics and Gynecology* 182:1127–1134 DOI 10.1067/mob.2000.105342.

Stephensen CB, Gildengorin G. 2000. Serum retinol, the acute phase response, and the apparent misclassification of vitamin A status in the third National Health and Nutrition Examination Survey. *American Journal of Clinical Nutrition* 72:1170–1178 DOI 10.1093/ajcn/72.5.1170.

Talwar DK, Azharuddin MK, Williamson C, Teoh YP, McMillan DC, St J O’Reilly D. 2005. Biological variation of vitamins in blood of healthy individuals. *Clinical Chemistry* 51:2145–2150 DOI 10.1373/clinchem.2005.056374.

Thurnham DI. 2014. Interactions between nutrition and immune function: using inflammation biomarkers to interpret micronutrient status. *The Proceedings of the Nutrition Society* 73:1–8 DOI 10.1017/S0029665113003662.
Thurnham D, McCabe G, Northrop-Clewes C, Nestel. 2003. Effects of subclinical infection on plasma retinol concentrations and assessment of prevalence of vitamin A deficiency: meta-analysis. *Lancet* **362**:2052–2058 DOI 10.1016/S0140-6736(03)15099-4.

Thurnham DI, McCabe LD, Haldar S, Wieringa FT, Northrop-Clewes CA, McCabe GP. 2010. Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. *American Journal of Clinical Nutrition* **92**:546–555 DOI 10.3945/ajcn.2010.29284.

Tuttle S, Aggett PJ, Campbell D, MacGillivray I. 1985. Zinc and copper nutrition in human pregnancy: a longitudinal study in normal primigravidae and in primigravidae at risk of delivering a growth retarded baby. *American Journal of Clinical Nutrition* **41**:1032–1041 DOI 10.1093/ajcn/41.5.1032.

Wang D, Du X, Zheng W. 2008. Alteration of saliva and serum concentrations of manganese, copper, zinc, cadmium and lead among career welders. *Toxicology Letters* **176**:40–47 DOI 10.1016/j.toxlet.2007.10.003.

Whittaker PG, Macphail S, Lind T. 1996. Serial hematologic changes and pregnancy outcome. *Obstetrics and Gynecology* **88**:33–39 DOI 10.1016/0029-7844(96)00095-6.

WHO. 2004. Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO expert consultation, Bangkok, Thailand, 21–30 1998. (accessed on 25 March 2019).

WHO. 2009. Report: WHO technical consultation on vitamin A in newborn health: mechanistic studies, Geneva, Switzerland, 1–3 December 2009. (accessed on 29 March 2019).

WHO. 2011. *Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System*. Geneva: World health Organization. Available at [http://wwwwho.int/vmnis/indicators/serum_ferritinpdf](http://wwwwho.int/vmnis/indicators/serum_ferritinpdf) (accessed on 26 July 2017).

WHO/CDC. 2007. Assessing the iron status of populations: report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the assessment of iron status at the population level. Geneva, Switzerland 6–8 2004. WHO Library Cataloguing-in-Publication Data 2007. WHO. Available at [http://whqlibdoc.who.int/publications/2004/9241593156_eng.pdf](http://whqlibdoc.who.int/publications/2004/9241593156_eng.pdf) (accessed on 21 July 2017).